AQUAPASS REFORM-HF Pivotal Trial Meets Primary Endpoint, Demonstrating Significant Fluid Removal in Heart Failure Patients
AQUAPASS ECCON™ System delivered a >7x increase in net fluid loss in congested heart failure patients not responding to high-dose diuretics, with a consistently high responder rate (91%) and no device-related adverse events NEWTON, Mass., Nov. 5, 2026 /PRNewswire/ -- AQUAPASS Medical,...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 89 stories mentioning NOV, the earliest published 7 Oct 2025.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.